Category: Market/Novel Tech

Month: 01 Apr 2012

Issue: not yet available

Neuron Systems Inc (J&J) and pSivida Corp enter evaluation deal for implantable delivery device

Neuron Systems Inc., Burlington, Massachusetts (an investment of Johnson & Johnson Development Corporation and Domain Associates) and pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Massachusetts, have announced a deal to evaluate pSivida’s “Durasert” bioerodible implantable delivery device system in combination with compounds from Neuron to treat dry age-related macular degeneration (AMD). The Technology Evaluation Agreement will govern the development of a sustained release drug delivery product for the treatment of back-of-the-eye diseases. Iluvien, pSivida’s most advanced product candidate, referenced in EURETINA Brief’s Clinical/Regulatory section, is licensed to Alimera Sciences, Inc., and will shortly enter national approval stage in the EU under the EU’s Decentralized Procedure (DCP). pSivida has also developed two FDA-approved products, Retisert, for the treatment of posterior uveitis and Vitrasert, for the treatment of AIDS-related cytomegalovirus (CMV) retinitis.

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]